Mission: The mission of the Neurologic Emergencies Treatment Trials (NETT) Network is to improve outcomes of patients with acute neurologic problems through innovative research focused on the emergent phase of patient care.

Vision: NETT will engage clinicians and providers at the front lines of emergency care to conduct large, simple multicenter clinical trials to answer research questions of clinical importance. The NETT structure will be utilized to achieve economies of scale enabling cost effective, high quality research.
If we did the things we are capable of, we would astound ourselves.

~Thomas Edison

Do you have an idea for a neurological emergency treatment that you would like studied? Please contact Kurt Denninghoff or Ginny Rizzo. We can assist you in developing a Protocol to run through the NETT. Watch your bright idea change clinical practice and improve the lives of our community members!

Check out the public disclosure video for RAMPART!
What are the inclusion/exclusion criteria for RAMPART?

The inclusion criteria for RAMPART:

- Continuous convulsive seizures upon arrival or for more than 5 minutes or
- Repeated convulsive seizures without waking up from post-ictal phase.

The exclusion criteria for RAMPART:

- Cardiac Arrest
- Heart Rate less than 40 BPM
- Medical Alert ID for allergy to midazolam or lorazepam.
- Wristband with the statement “RAMPART declined.”
- Known or obvious pregnancy
- Glucose Level < 60
- Major head trauma
- Prisoner or under arrest
- Weight estimated less than 13 kg per RAMPART tape measure
- Transport to a non-RAMPART receiving facility
UPDATES ON CURRENT NETT PROJECTS

ALIAS - Albumin in Acute Stroke Trial

**PI:** Myron Ginsberg, MD - University of Miami

**Status:** Open and enrolling in University Medical Center, Tucson. Two patients enrolled and six have been screened. Nationwide, there are 30 patients enrolled. University Physicians Hospital – Kino Campus will be ready to enroll patients in May.

**Primary Objective:** To ascertain whether high-dose human albumin (ALB) therapy confers neuroprotection in acute ischemic stroke over and above best standard of care. (Specifically, to determine whether ALB therapy increases the proportion of acute ischemic stroke patients with favorable outcome compared to placebo therapy at 3 months from randomization.)

RAMPART - Rapid Anticonvulsant Medication Prior to Arrival Trial

**PI:** Robert Silbergleit, MD - University of Michigan

**Status:** Public disclosure and community consultation activities progress with TV public service announcements and articles in local newspapers. Paramedic training has begun and hospital staff training will soon follow. Patient enrollment expected to start in July.

**Primary Objective:** To determine if the efficacy of intramuscular (IM) midazolam is not inferior to intravenous (IV) lorazepam by a pre-specified clinically unimportant absolute difference in the prehospital treatment of status epilepticus. Efficacy will be assessed by the proportion of subjects with termination of clinically evident seizure determined at arrival in the Emergency Department (ED) after a single dose of study medication and without use of rescue medication.

ProTECT - Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment
PI: David Wright, MD - Emory University

Status: Waiting to hear how much funding will be awarded.

Primary Objective: To determine the effectiveness of intravenous progesterone initiated within 4 hours of injury and administered for 72 hours as compared to placebo at improving functional outcome in patients with moderate to severe traumatic brain injury. Primary functional outcome is determined by Glasgow Outcome Scale – Enhanced (GOSE) measured at 6 months after injury. GOSE incorporates neurological recovery and mortality.

PI Profile: Bruce Coull, MD is the co-investigator for ALIAS II in Tucson. Dr. Coull is Professor of Neurology, Professor of Medicine, Associate Dean for Clinical Affairs, COM, Chief Medical Officer, UPH Practices, and William M. Feinberg Endowed Chair in Stroke Research at the University of Arizona. His research interests include cerebrovascular disease and lupus anticoagulant. He has written many articles and books on stroke. His latest book, co-author with Dr. Woodbury-Harris, is Clinical Trials in the Neurosciences. When Dr. Coull is not working, he spends time with his wife. He has 2 dogs and several varieties of birds. We are excited to have such an extraordinary physician be a part of AzNETT!
Please direct any questions you have regarding AzNETT to:

Principal Investigator, Tucson: Kurt Denninghoff, MD
kdenninghoff@aemrc.arizona.edu, phone 520-626-1551

Research Nurse Coordinator, Tucson: Ginny Rizzo, RN, CCRC
rizzo@aemrc.arizona.edu, phone 520-626-5250

Research Nurse Coordinator, Phoenix: Bruce Bamhart, RN, CEP
bbamhart@aemrc.arizona.edu, phone 602-827-2140

EMS Coordinator, Phoenix: Willie Haro, CEP
gharo@aemrc.arizona.edu, phone 602-827-2140.

AEMRC Administrative Assistant: Ronnie Benke
rbenke@aemrc.arizona.edu, phone 520-626-8819.

We look forward to working with you!